 Precision BioSciences Inc NASDAQ: DTIL has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsedrefractory RR non-Hodgkin lymphoma NHL PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate. 